Talking Precision Medicine

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling in precision medicine. We help accelerate the discovery and de-risk the development of novel therapeutics. From heterogeneous data and diverse information stores, we predict with confidence drug targets and biomarkers of tolerance, efficacy and outcome. Today we speak with Jonny Wray. Jonny is the Head of Discovery Informatics at e-therapeutics—a network-driven drug discovery company. He has extensive experience in applying mathematical and computational techniques to the modeling and analysis of biological systems, and is responsible for the conceptual formulation of the network-driven drug discovery approach pioneered at e-Therapeutics. We talk about everything from appreciating the complexity of biology to mechanistic modeling to discovering an entirely new chemical compound.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling in precision medicine. We help accelerate the discovery and de-risk the development of novel therapeutics. From heterogeneous data and diverse information stores, we predict with confidence drug targets and biomarkers of tolerance, efficacy and outcome. In this episode we speak with Asim Siddiqui. Asim is the CTO at NuMedii—a data driven drug discovery company. He has deep experience in computational biology, software engineering, next-generation sequencing, and cancer informatics, and is responsible for architecting and applying NuMedii’s AIDD (Artificial Intelligence for Drug Discovery) technology. We talk about leveraging public data for discovery, communicating between data scientists, bench scientists and other stakeholders, and the potential and challenges of using AI to advance drug development.